CLINICAL TRIALS PROFILE FOR EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

All Clinical Trials for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00799864 ↗	A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years	Recruiting	Janssen Sciences Ireland UC	Phase 2	2011-01-07	The purpose of this study is to evaluate the pharmacokinetics, safety and antiviral activity of rilpivirine (TMC278) 25 milligram (mg) or adjusted dose once daily in combination with an investigator-selected background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) (zidovudine [AZT], abacavir [ABC], or tenofovir disoproxil fumarate [TDF] in combination with lamivudine [3TC] or emtricitabine [FTC] in antiretroviral (ARV) treatment-naïve adolescents and children aged greater than or equal to (>=) 6 to less than (
NCT01252940 ↗	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF	Completed	Gilead Sciences	Phase 3	2010-11-01	The purpose of this randomized, open-label, multicenter, active-controlled Phase 3b study is to evaluate the noninferiority of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) single-tablet regimen (STR; also referred to as fixed-dose regimen or fixed-dose tablet) relative to regimens consisting of a ritonavir-boosted protease inhibitor (PI+RTV) and two nucleoside reverse transcriptase inhibitors (NRTIs) in virologically suppressed, HIV-1 infected subjects. The FTC/RPV/TDF STR could offer an attractive treatment option to patients who wish to simplify dosing by reducing pill burden or to improve the tolerability of their treatment. Participants will be randomized into 2 groups, the FTC/RPV/TDF STR group, in which participants will switch treatment regimens at the start of the study, and the Stay on Baseline Regimen (SBR)/Delayed Switch group, in which participants will remain on their baseline regimen during the first 24 weeks of the study (designed to provide an initial active control), and may switch to the FTC/RPV/TDF STR at the Week 24 visit. After the 48-week study analysis period, participants may continue to receive the FTC/RPV/TDF STR per protocol before switching to a commercially available source.
NCT01286740 ↗	Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR	Completed	Gilead Sciences	Phase 2	2011-01-01	The purpose of this Phase 2b study was to evaluate the efficacy and safety of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR, after switching from the efavirenz (EFV)/FTC/TDF STR at baseline, in maintaining HIV-1 RNA < 50 copies/mL at Week 12. HIV-infected patients were enrolled if they had received EFV/FTC/TDF for ≥ 3 months prior to study start, were experiencing safety or tolerability concerns (in particular, EFV-related intolerance), and wished to change to an alternate, better-tolerated regimen.
NCT01309243 ↗	Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiret	Completed	Gilead Sciences	Phase 3	2011-02-01	The purpose of the study was to evaluate the safety and efficacy of the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) compared with the efavirenz (EFV)/FTC/TDF STR in HIV-1 infected adults who had not previously received treatment with antiretroviral medications. Participants were randomized in a 1:1 ratio to receive one of the study treatments. Randomization was stratified by HIV-1 RNA level (≤ 100,000 copies/mL or > 100,000 copies/mL) at screening. A treatment duration of 96 weeks was planned, with the option for subjects in FTC/RPV/TDF STR arm to receive treatment following the Week 96 visit until FTC/RPV/TDF STR is commercially available or until Gilead Sciences elects to terminate development in that country.
NCT01500616 ↗	Telaprevir Open-Label Study in Co-Infected Patients	Completed	Janssen-Cilag International NV	Phase 3	2012-06-01	The purpose of this study is to collect safety and tolerability data on telaprevir treatment in combination with Peg-IFN-alfa and RBV in patients with HIV/genotype 1 chronic HCV coinfection with severe fibrosis or compensated cirrhosis who are not eligible for enrollment into an ongoing clinical study of telaprevir.
NCT01709084 ↗	A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment	Completed	Janssen-Cilag International NV	Phase 3	2013-10-02	The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) levels less than 400 copies per mL after 48 weeks of randomized treatment with tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus TDF/FTC/efavirenz (TDF/FTC/EFV).

Clinical Trial Conditions for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Condition Name

Condition Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
HIV-1 Infection	7
Quality of Life	1
Depression/Anxiety	1
Healthy	1

Condition MeSH

Condition MeSH for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Intervention	Trials
Immunologic Deficiency Syndromes	2
Hepatitis C	1
Hepatitis A	1
Hepatitis	1

Clinical Trial Locations for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Trials by Country

Trials by Country for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
United States	130
Canada	16
Germany	7
United Kingdom	6
Italy	5

Trials by US State

Trials by US State for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Location	Trials
Texas	7
Missouri	7
District of Columbia	7
California	7
Illinois	6

Clinical Trial Progress for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Clinical Trial Phase

Clinical Trial Phase for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	6
Phase 2	2

Clinical Trial Status

Clinical Trial Status for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Clinical Trial Phase	Trials
Completed	10
Recruiting	1

Clinical Trial Sponsors for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate

Sponsor Name

Sponsor Name for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Gilead Sciences	6
Janssen-Cilag International NV	2
Janssen Pharmaceutical K.K.	1

Sponsor Type

Sponsor Type for emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate
Sponsor	Trials
Industry	10
Other	2
NIH	1

Clinical trials update, market analysis and projection for emtricitabine/rilpivirine hydrochloride/tenofovir disoproxil fumarate (TDF) fixed-dose combination

Last updated: July 30, 2026

What is the current clinical-trials and pipeline status for emtricitabine/rilpivirine/TDF?

Answer: The fixed-dose combination (FDC) of emtricitabine (FTC), rilpivirine hydrochloride (RPV-HCl), and tenofovir disoproxil fumarate (TDF) is an established antiretroviral regimen with limited active development shown in public registries for new FTC/RPV/TDF-specific indications. The dominant pipeline impact comes from (1) newer generational HIV agents that compete on tolerability, dosing frequency, and renal/bone safety, and (2) regulator- and sponsor-driven label expansions for established components rather than stand-alone FTC/RPV/TDF redevelopment.

Which trials most affect FTC/RPV/TDF near-term demand?

Publicly visible clinical activity affecting market trajectory typically falls into three buckets:

1. Comparative efficacy and tolerability in real-world cohorts (often not interventional).
2. Studies supporting switches off TDF to TAF or other TDF-sparing strategies.
3. Investigations into long-acting or simplified regimens that compete against oral single-tablet regimens.

Key implication for projections: demand for FTC/RPV/TDF is less sensitive to “brand-new” FTC/RPV/TDF trials and more sensitive to guideline and switching patterns driven by TDF safety and convenience.

How do trial readouts translate into switching risk?

• Patients switch away from TDF when renal function declines, bone mineral density loss is a concern, or clinicians prefer TAF-based regimens.
• RPV contributes meal and gastric-acidity considerations, which can drive adherence variability and payer preference shifts to regimens with fewer food interactions or higher forgiveness.

How big is the FTC/RPV/TDF market today and what is the demand driver mix?

Answer: The FTC/RPV/TDF market is a subset of the global antiretroviral therapy (ART) market and is driven by (1) penetration of RPV-based regimens in treatment-naïve and suppressed populations, (2) clinician preference for fixed-dose convenience, (3) payer formularies and rebate dynamics, and (4) patient adherence to RPV’s administration requirements.

Core demand segments

1. Treatment-naïve patients using an NNRTI-based single-tablet regimen aligned to RPV’s labeling constraints (including viral load considerations at initiation).
2. Virologically suppressed patients maintained on the regimen as a continuation strategy.
3. Switch populations moving from other oral ART to a fixed-dose regimen for simplicity, cost, or formulary alignment.

What drives share loss?

• TDF safety positioning versus TAF-based alternatives (renal and bone considerations).
• Convenience competition: long-acting injectables are incremental share threats in many markets even if uptake is uneven.
• Tolerability and drug interaction management: RPV requires attention to acid-reducing agents and certain concomitant drugs.

What is the competitive landscape for FTC/RPV/TDF and how does it compare with rival single-tablet regimens?

Answer: FTC/RPV/TDF competes primarily with other oral fixed-dose ART regimens (especially TAF-based NRTI backbones and INSTI-based combinations). Competitive pressure increases as INSTI-based regimens and TAF combinations expand payer access.

Direct comparators by clinical posture

• INSTI-based single-tablets: often selected for higher genetic barrier-to-resistance profiles and fewer food interactions.
• TAF-based NRTI combinations: reduce renal and bone risks versus TDF.
• Other RPV-containing oral regimens: compete on formulary tiering and the availability of alternative NRTI backbones.

Where RPV can still win

• Fixed-dose convenience and established efficacy in suppressed patients.
• Certain payer channels favoring RPV-based options due to pricing and contracting.

When does FTC/RPV/TDF lose exclusivity and what are the generic and biosimilar risks?

Answer: FTC/RPV/TDF is not protected by a single monolithic exclusivity event that governs entry across the full product universe; instead, commercial risk is a function of the expiration of relevant composition-of-matter and formulation/method patents for each active ingredient and the specific FDC combination. In practical market terms, generic and authorized versions of NRTI backbones are already widely available in the US and internationally, which structurally limits long-term brand-like economics.

Regulatory entry dynamics that matter for projections

• Multiple-source availability typically compresses unit pricing.
• Rebate intensity and formulary design drive channel share more than incremental clinical trial gains.
• Any remaining protected usage scenarios depend on specific product forms, dosing strengths, or label-protected combinations.

What is the FDA and Orange Book status of FTC/RPV/TDF products that shapes commercialization?

Answer: FTC/RPV/TDF commercialization in the US is governed by FDA approval for the FDC strengths and by Orange Book-listed patents tied to those specific NDA products. Because generic competition typically starts once relevant listed patents expire or are challenged under paragraph IV, the practical projection depends on how many Orange Book patents remain in-force at any point.

How does Orange Book listing intensity impact pricing?

A dense Orange Book estate can delay entry of AB-rated generics. Once entry occurs, pricing typically declines rapidly and growth depends on volume rather than price.

How strong is the patent estate around FTC/RPV/TDF and which patents are most likely to block generic entry?

Answer: The most litigation-relevant patents for FTC/RPV/TDF historically include:

• composition-of-matter for the individual actives (FTC, RPV, TDF prodrug/form),
• specific salts and polymorphs (for RPV-HCl and prodrug forms),
• combination claims for the FDC,
• formulation and manufacturing-process claims for the single-tablet presentation,
• and, in some cases, method-of-use claims for patient selection (viral load thresholds, resistance-associated mutations) or administration constraints.

What matters for business outcomes

• Whether any still-listed patents are product-specific enough to block substitution at the pharmacy level.
• Whether ANDA litigation has already resulted in non-infringement findings or settlements that allow early entry dates.

What Paragraph IV challenges and patent litigation affect FTC/RPV/TDF pricing and timing?

Answer: The FTC/RPV/TDF market’s risk profile is shaped by the general ANDA wave for mature HIV combinations: once multiple generics are authorized, incremental patent litigation becomes less likely to materially change the long-term volume trajectory, but can influence short-window pricing.

How to interpret litigation timing for forecast windows

• Settlement-driven “at-risk” entry can create step-down pricing in discrete quarters.
• Court rulings or carve-outs can sustain niche pricing where entry is delayed in specific dosage forms or strengths.

How do treatment guidelines and payer policy affect FTC/RPV/TDF uptake and decline?

Answer: Uptake depends on guideline recommendations for NNRTI-based regimens and on payer preference for regimens with favorable safety and fewer interaction issues. Decline is driven by shifting first-line and switch preferences toward INSTI-based and TAF-based regimens.

Policy levers that change volume

• Formulary tier placement (preferred vs restricted).
• Utilization management for RPV (food, acid suppression guidance, regimen switching criteria).
• Step therapy for INSTI-based alternatives.

Market projection for FTC/RPV/TDF: what is the expected 3- to 7-year trajectory?

Answer: The most likely trajectory is steady-to-declining share in many mature markets, with growth constrained by (1) competition from INSTI-based and TAF-based regimens, and (2) TDF safety-driven switches. Forecasting should treat the drug as a mature ART franchise with volume growth tied to patient population expansion in low- and middle-income countries and stable replacement demand in suppressed patients, offset by share loss to newer regimens in higher-income markets.

Base-case projection logic (volume-first, price-down)

• Price: downward as generic competition remains entrenched.
• Volume: linked to diagnosed HIV population growth and continuity of suppression.
• Share: declines gradually as guidelines and formularies shift toward INSTI/TAF.
• Switch rates: increase with renal/bone risk awareness and clinician preference trends.

Scenario view for planning

1. Conservative (faster share erosion): faster switching from TDF and RPV interaction management leads to sharper volume loss.
2. Base case (steady maintenance): suppressed-patient stability keeps volume modest; share erosion continues at a moderate pace.
3. Upside (payer-optimized access): continued contracting keeps regimen affordable; slower switching maintains volume longer.

What additional commercial metrics should be monitored for FTC/RPV/TDF?

Answer: The forecast should be monitored against:

• changes in formulary position and restriction criteria (especially around RPV and acid-reducing agents),
• TDF-to-TAF switch rates,
• incidence of regimen simplification in suppressed patients,
• and reimbursement trends in key geographies.

Leading indicators

• Quarterly changes in prescriptions (or dispensed units) segmented by line of therapy.
• Growth of TAF-based and INSTI-based alternatives within the same payer networks.
• Product-level pricing and discount rate changes after generic entry updates.

---

Key Takeaways

• FTC/RPV/TDF is a mature oral ART regimen with limited near-term differentiation from new FTC/RPV/TDF-specific interventional trials.
• Demand is driven by fixed-dose convenience and maintenance in suppressed patients, but share is pressured by TDF safety positioning and competition from INSTI-based and TAF-based single-tablet regimens.
• Generic availability makes the market structurally price-compressed; business outcomes hinge on formulary position, switching dynamics, and managed-care restrictions rather than trial-driven breakthroughs.
• Forecasts should be volume-first with gradual share decline assumptions in higher-income markets and more stable volume retention in channels where cost and continuity of suppression dominate.

---

FAQs

1. How does RPV’s food and drug interaction profile affect persistence on FTC/RPV/TDF in real-world use?
2. What are the main clinical reasons clinicians switch patients from TDF-based regimens to TAF-based alternatives?
3. How do payer restrictions on NNRTI regimens shift demand among oral fixed-dose HIV combinations?
4. What market events typically cause the fastest unit-price declines for mature HIV single-tablet regimens?
5. Which endpoints in real-world cohorts most strongly predict switching away from FTC/RPV/TDF?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drugs@FDA: FDA Approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. ClinicalTrials.gov. (n.d.). Search results for emtricitabine rilpivirine tenofovir disoproxil fumarate. U.S. National Library of Medicine. https://clinicaltrials.gov/